ACAD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 28.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $3,042,092.93

ACADIA Pharmaceuticals Insider Trading History Chart

ACADIA Pharmaceuticals Share Price & Price History

^$16.27

▲ +0.06 (0.37%)

As of 11/20/2024 01:00 AM ET

Days: 30 | 90 | 365

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

ACADIA Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Brendan Teehan	COO	Sell	10,329	$16.81	$173,630.49	62,105
11/19/2024	James Kihara	Insider	Sell	4,073	$16.81	$68,467.13	19,863
11/19/2024	Mark C. Schneyer	CFO	Sell	10,259	$16.81	$172,453.79	53,302
8/19/2024	Brendan Teehan	COO	Sell	9,534	$15.28	$145,679.52	52,177
8/19/2024	Mark C. Schneyer	CFO	Sell	9,733	$15.28	$148,720.24	43,735
8/19/2024	Stephen R. Davis	CEO	Sell	31,747	$15.28	$485,094.16	186,555
6/10/2024	Mark C. Schneyer	CFO	Sell	975	$14.79	$14,420.25	34,564
5/2/2024	Brendan Teehan	COO	Sell	3,477	$16.94	$58,900.38	42,133
5/2/2024	James Kihara	Insider	Sell	1,326	$16.94	$22,462.44	14,370
5/2/2024	Mark C. Schneyer	CFO	Sell	3,503	$16.94	$59,340.82	32,053
5/2/2024	Stephen R. Davis	CEO	Sell	11,427	$16.94	$193,573.38	155,231
4/8/2024	Brendan Teehan	COO	Sell	2,568	$17.87	$45,890.16	38,796
4/8/2024	James Kihara	Insider	Sell	1,790	$17.87	$31,987.30	13,100
4/8/2024	Mark C. Schneyer	CFO	Sell	2,716	$17.87	$48,534.92	28,742
4/8/2024	Stephen R. Davis	CEO	Sell	26,574	$17.87	$474,877.38	144,267
3/27/2024	Brendan Teehan	COO	Sell	5,140	$17.90	$92,006.00	36,340
3/27/2024	Mark C. Schneyer	CFO	Sell	5,434	$17.90	$97,268.60	26,183
3/27/2024	Stephen R. Davis	CEO	Sell	17,714	$17.90	$317,080.60	118,842
2/26/2024	Brendan Teehan	COO	Sell	624	$24.67	$15,394.08	31,432
2/26/2024	James Kihara	Insider	Sell	474	$24.67	$11,693.58	11,391
2/26/2024	Mark C. Schneyer	CFO	Sell	772	$24.67	$19,045.24	21,067
2/26/2024	Stephen R. Davis	CEO	Sell	5,577	$24.67	$137,584.59	101,890
1/8/2024	Austin D Kim	EVP	Sell	590	$29.96	$17,676.40	46,901
1/8/2024	Brendan Teehan	COO	Sell	731	$29.96	$21,900.76	30,949
1/8/2024	Stephen R. Davis	CEO	Sell	3,732	$29.96	$111,810.72	96,521
12/15/2023	James Kihara	Insider	Sell	2,000	$28.30	$56,600.00	11,025
11/20/2023	Brendan Teehan	COO	Sell	4,960	$22.64	$112,294.40	30,393
11/20/2023	James Kihara	Insider	Sell	1,985	$22.64	$44,940.40	13,025
11/20/2023	Mark C. Schneyer	CFO	Sell	5,108	$22.64	$115,645.12	20,486
10/6/2023	Austin D Kim	EVP	Sell	16,369	$21.96	$359,463.24	45,857
10/6/2023	Stephen R. Davis	CEO	Sell	51,563	$21.96	$1,132,323.48	89,131
9/15/2023	James Kihara	Insider	Sell	2,000	$25.88	$51,760.00	10,778
8/21/2023	Mark C. Schneyer	CFO	Sell	10,000	$29.00	$290,000.00	15,682
7/14/2023	Stephen R. Davis	CEO	Sell	100,000	$30.04	$3,004,000.00	36,695
7/11/2023	Stephen R. Davis	CEO	Sell	16,498	$25.00	$412,450.00	91,799
6/15/2023	James Kihara	Insider	Sell	2,000	$24.15	$48,300.00	9,144
6/12/2023	Laura Brege	Director	Sell	4,500	$24.87	$111,915.00	13,502
6/8/2023	Mark C. Schneyer	CFO	Sell	974	$25.02	$24,369.48	22,824
5/23/2023	Bros. Advisors Lp Baker	Director	Buy	209,053	$25.41	$5,312,036.73	38,811,515
5/17/2023	Brendan Teehan	COO	Sell	14,869	$22.50	$334,552.50	24,356
5/17/2023	James Kihara	Insider	Sell	5,947	$22.50	$133,807.50	11,144
5/17/2023	Mark C. Schneyer	CFO	Sell	15,310	$22.50	$344,475.00	21,905
5/1/2023	Austin D Kim	EVP	Sell	917	$21.18	$19,422.06	25,513
5/1/2023	Brendan Teehan	COO	Sell	548	$21.18	$11,606.64	9,487
5/1/2023	Stephen R. Davis	CEO	Sell	7,806	$21.18	$165,331.08	108,297
4/10/2023	James Kihara	Insider	Sell	523	$18.14	$9,487.22	5,197
4/6/2023	Austin D Kim	EVP	Sell	1,456	$18.16	$26,440.96	23,425
4/6/2023	Brendan Teehan	COO	Sell	1,751	$18.16	$31,798.16	8,468
4/6/2023	James Kihara	Insider	Sell	701	$18.16	$12,730.16	4,231
4/6/2023	Mark C. Schneyer	CFO	Sell	1,916	$18.16	$34,794.56	7,477
4/6/2023	Stephen R. Davis	CEO	Sell	8,582	$18.16	$155,849.12	100,478
2/24/2023	Austin D Kim	EVP	Sell	803	$18.78	$15,080.34	20,108
2/24/2023	Brendan Teehan	COO	Sell	461	$18.78	$8,657.58	5,195
2/24/2023	James Kihara	Insider	Sell	350	$18.78	$6,573.00	2,923
2/24/2023	Mark C. Schneyer	CFO	Sell	577	$18.78	$10,836.06	4,118
2/24/2023	Stephen R. Davis	CEO	Sell	3,851	$18.78	$72,321.78	91,727
1/12/2023	Laura Brege	Director	Sell	12,500	$18.25	$228,125.00
1/9/2023	Austin D Kim	EVP	Sell	589	$17.13	$10,089.57	18,697
1/9/2023	Brendan Teehan	COO	Sell	532	$17.13	$9,113.16	4,549
1/9/2023	Stephen R. Davis	CEO	Sell	3,904	$17.13	$66,875.52	84,633
11/21/2022	Srdjan R Stankovic	President	Sell	1,847	$15.07	$27,834.29	61,234
10/15/2022	Srdjan R Stankovic	President	Sell	1,326	$15.81	$20,964.06	56,831
10/15/2022	Stephen R. Davis	CEO	Sell	2,804	$15.81	$44,331.24	79,009
6/9/2022	Mark C. Schneyer	CFO	Sell	653	$17.91	$11,695.23	3,342
5/2/2022	Austin D Kim	EVP	Sell	894	$18.18	$16,252.92	16,742
5/2/2022	Brendan Teehan	COO	Sell	552	$18.18	$10,035.36	3,437
5/2/2022	Srdjan R Stankovic	President	Sell	2,865	$18.18	$52,085.70	55,188
5/2/2022	Stephen R. Davis	CEO	Sell	5,483	$18.18	$99,680.94	75,875
4/8/2022	James Kihara	insider	Sell	1,025	$27.05	$27,726.25	2,433
2/23/2022	Austin D Kim	EVP	Sell	782	$23.80	$18,611.60
2/23/2022	Brendan Teehan	COO	Sell	472	$23.80	$11,233.60
2/23/2022	James Kihara	Insider	Sell	359	$23.80	$8,544.20
2/23/2022	Srdjan R Stankovic	President	Sell	1,501	$23.80	$35,723.80
2/23/2022	Stephen R. Davis	CEO	Sell	3,928	$23.80	$93,486.40
11/22/2021	Srdjan R Stankovic	President	Sell	2,803	$19.01	$53,285.03

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

SEC Filings (Institutional Ownership Changes) for ACADIA Pharmaceuticals (NASDAQ:ACAD)

96.71% of ACADIA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ACADIA Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/18/2024	Arete Wealth Advisors LLC	11,825	$0.18M	0.0%	-24.7%	0.007%
11/18/2024	Neo Ivy Capital Management	3,482	$54K	0.0%	-98.3%	0.002%
11/16/2024	Geode Capital Management LLC	2,875,540	$44.23M	0.0%	+1.1%	1.728%
11/15/2024	Barclays PLC	277,565	$4.27M	0.0%	+126.2%	0.167%
11/15/2024	Y Intercept Hong Kong Ltd	50,544	$0.78M	0.0%	-43.7%	0.030%
11/15/2024	Wellington Management Group LLP	62,585	$0.96M	0.0%	-3.4%	0.038%
11/15/2024	Sphera Funds Management LTD.	252,539	$3.88M	0.6%	-22.9%	0.152%
11/15/2024	State Street Corp	5,973,874	$91.88M	0.0%	+3.0%	3.590%
11/15/2024	Iron Triangle Partners LP	750,000	$11.54M	1.6%	N/A	0.451%
11/15/2024	Jacobs Levy Equity Management Inc.	1,211,314	$18.63M	0.1%	-10.6%	0.728%
11/15/2024	Cinctive Capital Management LP	39,040	$0.60M	0.0%	-12.0%	0.023%
11/15/2024	Erste Asset Management GmbH	242,300	$3.80M	0.0%	N/A	0.146%
11/14/2024	Edgestream Partners L.P.	219,329	$3.37M	0.1%	+141.1%	0.132%
11/14/2024	PDT Partners LLC	13,218	$0.20M	0.0%	N/A	0.008%
11/14/2024	Fred Alger Management LLC	3,186,389	$49.01M	0.2%	+17.8%	1.915%
11/14/2024	Eventide Asset Management LLC	577,500	$8.88M	0.2%	N/A	0.347%
11/14/2024	Rockefeller Capital Management L.P.	1,139,934	$17.53M	0.0%	+19.5%	0.685%
11/14/2024	Walleye Capital LLC	40,806	$0.63M	0.0%	-64.6%	0.025%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	189,739	$2.92M	0.0%	-12.8%	0.114%
11/14/2024	Stonepine Capital Management LLC	196,895	$3.03M	1.9%	+3,837.9%	0.118%
11/13/2024	BNP Paribas Financial Markets	223,618	$3.44M	0.0%	+259.0%	0.134%
11/13/2024	FMR LLC	97,358	$1.50M	0.0%	-95.9%	0.059%
11/13/2024	Advantage Alpha Capital Partners LP	24,914	$0.38M	0.1%	-34.6%	0.015%
11/13/2024	The Manufacturers Life Insurance Company	413,269	$6.36M	0.0%	-10.6%	0.248%
11/13/2024	Dynamic Technology Lab Private Ltd	22,229	$0.34M	0.0%	N/A	0.013%
11/13/2024	Fisher Asset Management LLC	194,599	$2.99M	0.0%	+19.7%	0.117%
11/12/2024	Algert Global LLC	549,456	$8.45M	0.2%	+2.9%	0.331%
11/12/2024	Charles Schwab Investment Management Inc.	1,271,135	$19.55M	0.0%	-0.3%	0.766%
11/12/2024	Massachusetts Financial Services Co. MA	61,051	$0.94M	0.0%	-2.4%	0.037%
11/9/2024	Landscape Capital Management L.L.C.	16,562	$0.26M	0.0%	N/A	0.010%
11/9/2024	Intech Investment Management LLC	37,683	$0.58M	0.0%	N/A	0.023%
11/8/2024	Advisors Asset Management Inc.	21,087	$0.32M	0.0%	+13.4%	0.013%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	972,665	$14.96M	0.1%	-22.4%	0.586%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	31,405	$0.48M	0.0%	N/A	0.019%
11/8/2024	Phocas Financial Corp.	60,215	$0.93M	0.0%	-5.9%	0.036%
11/7/2024	Quest Partners LLC	3,520	$54K	0.0%	+42.3%	0.002%
11/6/2024	Natixis Advisors LLC	40,488	$0.62M	0.0%	+58.6%	0.024%
11/6/2024	Oppenheimer Asset Management Inc.	37,429	$0.58M	0.0%	+26.6%	0.023%
11/5/2024	Victory Capital Management Inc.	97,130	$1.49M	0.0%	+2.9%	0.059%
11/5/2024	GSA Capital Partners LLP	67,096	$1.03M	0.1%	-62.9%	0.040%
11/5/2024	WCM Investment Management LLC	286,527	$4.50M	0.0%	-1.0%	0.173%
11/4/2024	Los Angeles Capital Management LLC	44,297	$0.68M	0.0%	-13.1%	0.027%
11/1/2024	Atria Investments Inc	24,437	$0.38M	0.0%	+10.8%	0.015%
10/31/2024	Principal Financial Group Inc.	129,551	$1.99M	0.0%	+67.8%	0.078%
10/30/2024	AlphaCentric Advisors LLC	40,000	$0.62M	0.5%	-60.0%	0.024%
10/29/2024	Emerald Advisers LLC	830,829	$12.78M	0.5%	+2.7%	0.503%
10/29/2024	Emerald Mutual Fund Advisers Trust	574,810	$8.84M	0.5%	+2.9%	0.348%
10/28/2024	Rice Hall James & Associates LLC	717,146	$11.03M	0.6%	-3.5%	0.434%
10/28/2024	US Bancorp DE	32,934	$0.51M	0.0%	+2,084.0%	0.020%
10/25/2024	China Universal Asset Management Co. Ltd.	31,903	$0.49M	0.1%	+64.4%	0.019%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	5,999	$94K	0.0%	+21.6%	0.004%
10/23/2024	Garrison Point Advisors LLC	10,576	$0.16M	0.1%	N/A	0.006%
10/23/2024	Values First Advisors Inc.	1,754	$27K	0.0%	N/A	0.001%
10/23/2024	Hennion & Walsh Asset Management Inc.	95,834	$1.47M	0.1%	-6.5%	0.058%
10/19/2024	Allspring Global Investments Holdings LLC	121,625	$1.87M	0.0%	+11.7%	0.074%
10/11/2024	Creative Planning	25,061	$0.39M	0.0%	+71.4%	0.015%
10/8/2024	Park Place Capital Corp	1,600	$25K	0.0%	N/A	0.001%
10/5/2024	Handelsbanken Fonder AB	47,633	$0.73M	0.0%	+16.7%	0.029%
10/3/2024	SG Americas Securities LLC	517,124	$7.95M	0.0%	+419.8%	0.313%
9/20/2024	Healthcare of Ontario Pension Plan Trust Fund	70,524	$1.15M	0.0%	-62.7%	0.043%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	4,538	$74K	0.0%	-72.5%	0.003%
9/5/2024	Sanctuary Advisors LLC	91,834	$1.54M	0.0%	N/A	0.056%
8/21/2024	Truist Financial Corp	50,006	$0.81M	0.0%	+16.0%	0.030%
8/21/2024	Stonepine Capital Management LLC	5,000	$81K	0.1%	N/A	0.003%
8/16/2024	Quarry LP	8,055	$0.13M	0.0%	+34.3%	0.005%
8/16/2024	Capital Impact Advisors LLC	24,540	$0.40M	1.1%	+153.4%	0.015%
8/16/2024	Algert Global LLC	534,143	$8.68M	0.3%	+50.7%	0.323%
8/16/2024	Cim Investment Management Inc.	15,082	$0.25M	0.1%	-19.2%	0.009%
8/15/2024	Scientech Research LLC	41,586	$0.68M	0.1%	N/A	0.025%
8/15/2024	Mackenzie Financial Corp	19,900	$0.32M	0.0%	-65.5%	0.012%
8/15/2024	The Manufacturers Life Insurance Company	462,078	$7.51M	0.0%	-60.6%	0.280%
8/15/2024	Millennium Management LLC	2,937,714	$47.74M	0.0%	+36.2%	1.778%
8/15/2024	D. E. Shaw & Co. Inc.	2,934,926	$47.69M	0.0%	+11.1%	1.776%
8/15/2024	Dark Forest Capital Management LP	32,910	$0.54M	0.1%	N/A	0.020%
8/15/2024	AQR Capital Management LLC	36,191	$0.59M	0.0%	-23.9%	0.022%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	4,538	$74K	0.0%	-72.5%	0.003%
8/15/2024	Point72 Europe London LLP	50,600	$0.82M	0.1%	N/A	0.031%
8/14/2024	Squarepoint Ops LLC	848,441	$13.79M	0.0%	-14.2%	0.514%
8/14/2024	Fred Alger Management LLC	2,704,439	$43.95M	0.2%	+19.8%	1.637%
8/14/2024	Cubist Systematic Strategies LLC	666,578	$10.83M	0.1%	+47.6%	0.402%
8/14/2024	Marshall Wace LLP	2,774,353	$45.08M	0.1%	+431.1%	1.679%
8/14/2024	Bank of Montreal Can	96,225	$1.57M	0.0%	N/A	0.058%
8/14/2024	HighVista Strategies LLC	25,878	$0.42M	0.2%	N/A	0.016%
8/14/2024	ProShare Advisors LLC	26,626	$0.43M	0.0%	-20.7%	0.016%
8/14/2024	Profund Advisors LLC	56,555	$0.92M	0.0%	-8.7%	0.034%
8/13/2024	Thrivent Financial for Lutherans	78,292	$1.27M	0.0%	-4.1%	0.047%
8/13/2024	Sei Investments Co.	32,734	$0.53M	0.0%	-5.8%	0.020%
8/13/2024	Canada Pension Plan Investment Board	738,700	$12M	0.0%	+11.7%	0.447%
8/13/2024	Public Employees Retirement Association of Colorado	13,821	$0.23M	0.0%	-9.9%	0.008%
8/12/2024	XTX Topco Ltd	36,520	$0.59M	0.1%	N/A	0.022%
8/9/2024	Edgestream Partners L.P.	90,957	$1.48M	0.1%	+46.9%	0.055%
8/9/2024	Renaissance Technologies LLC	476,000	$7.74M	0.0%	-17.0%	0.288%
8/9/2024	Dimensional Fund Advisors LP	649,150	$10.55M	0.0%	N/A	0.393%
8/9/2024	Massachusetts Financial Services Co. MA	62,530	$1.02M	0.0%	+3.5%	0.038%
8/8/2024	Envestnet Asset Management Inc.	107,543	$1.75M	0.0%	+1.9%	0.065%
8/8/2024	Oppenheimer Asset Management Inc.	29,557	$0.48M	0.0%	+10.6%	0.018%
8/8/2024	Jupiter Asset Management Ltd.	1,060,840	$17.24M	0.2%	-33.9%	0.642%
8/8/2024	American Century Companies Inc.	73,148	$1.19M	0.0%	+76.7%	0.044%
8/8/2024	Rice Hall James & Associates LLC	742,935	$12.07M	0.7%	+11.8%	0.450%
8/7/2024	Headlands Technologies LLC	57,209	$0.93M	0.1%	+2,099.5%	0.035%

Data available starting January 2016

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.27

$16.05

$16.39

50 Day Range

MA: $15.61

$14.29

$18.27

52 Week Range

Now: $16.27

$14.15

$32.59

Volume

1,087,297 shs

Average Volume

1,679,200 shs

Market Capitalization

$2.71 billion

P/E Ratio

20.86

Dividend Yield

N/A

Beta

0.38

Who are the company insiders with the largest holdings of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top insider investors include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Brendan Teehan (COO)
Srdjan R Stankovic (President)
Mark C Schneyer (CFO)
Austin D Kim (EVP)
James Kihara (Insider)
Laura Brege (Director)
Learn More about top insider investors at ACADIA Pharmaceuticals.
Who are the major institutional investors of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top institutional shareholders include:
State Street Corp — 3.59%
Fred Alger Management LLC — 1.91%
Geode Capital Management LLC — 1.73%
Charles Schwab Investment Management Inc. — 0.77%
Jacobs Levy Equity Management Inc. — 0.73%
Rockefeller Capital Management L.P. — 0.69%
Learn More about top institutional investors of ACADIA Pharmaceuticals stock.
Which institutional investors are selling ACADIA Pharmaceuticals stock?: In the last quarter, ACAD stock was sold by these institutional investors:
FMR LLC
Connor Clark & Lunn Investment Management Ltd.
Neo Ivy Capital Management
Jacobs Levy Equity Management Inc.
GSA Capital Partners LLP
Sphera Funds Management LTD.
Walleye Capital LLC
AlphaCentric Advisors LLC
During the previous year, company insiders that have sold ACADIA Pharmaceuticals company stock include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Brendan Teehan (COO)
Srdjan R Stankovic (President)
Mark C Schneyer (CFO)
Learn More investors selling ACADIA Pharmaceuticals stock.
Which institutional investors are buying ACADIA Pharmaceuticals stock?: During the previous quarter, ACAD stock was purchased by institutional investors including:
Iron Triangle Partners LP
Eventide Asset Management LLC
Fred Alger Management LLC
SG Americas Securities LLC
Erste Asset Management GmbH
Stonepine Capital Management LLC
Rockefeller Capital Management L.P.
State Street Corp